Articles By Rob Wright, Chief Editor

In Need Of A Biopharma Bright Spot?
In Need Of A Biopharma Bright Spot? If you are anything like me, you are probably in need of a little more positivity. And despite what many mass media outlets might lead you to believe, the biopharmaceutical industry has a plethora of bright spots.  Continue Reading...
  • Can David Hung Lead Axovant To Alzheimer’s Success?
    Can David Hung Lead Axovant To Alzheimer’s Success?

    Why would David Hung, M.D., a veteran pharma executive, forgo retirement (after a big acquisition payday), join Axovant Sciences, and then invest $10 million of his own money into the small company? Our chief editor sat down with him to get the answers to those questions and more.

  • Can We Make Innovative Medicines Affordable?
    Can We Make Innovative Medicines Affordable?

    “As the price of pharmaceuticals continues to rise, we are seeing greater resistance from [U.S.] patients being willing to pay,” says Dr. Steven Miller. The SVP and chief medical officer at Express Scripts is giving his opening remarks during the Our Common Goal: Ensuring Access and Affordability of Innovative Medicines session at the 2017 BIO International Convention in San Diego. Miller pulls no punches with his fellow biopharmaceutical executive panelists, setting the tone that today’s discussion on drug pricing will not be a “hugfest.”

  • Why <em>Every</em> Company Needs A Bio Strategy
    Why Every Company Needs A Bio Strategy

    Today we stand on the precipice overlooking a new frontier — the century of biology, and businesses of all kinds need to be prepared to not only embrace what is coming, but have a strategy for how to leverage biology for the betterment of their businesses and the good of the planet.

  • What Is BIO Hoping To See Among Session Submissions For 2018?
    What Is BIO Hoping To See Among Session Submissions For 2018?

    Life Science Leader Chief Editor Rob Wright is cochairing the 2018 BIO educational program planning committee. In this blog he talks about why this was the earliest the planning committee has ever met and what you can do to submit interesting and novel session proposals that will get the attention of the committee.

  • The Essentials Of Your BIO 2018 Educational Session Proposal
    The Essentials Of Your BIO 2018 Educational Session Proposal

    Next week, BIO will invite biopharmaceutical industry experts to submit educational topic session proposals for the 2018 BIO International Convention in Boston, June 4 - 7. The 2018 call for sessions and speakers opens on Thursday, September 14, and closes on Thursday, October 12, 2017. As I have (once again) agreed to serve as a BIO educational program planning committee co-chair, I have a vested interest in its success. My goal in helping biopharma’s largest and most influential global event, is to assist in creating such a strong educational program, that when you see this year’s offerings you will deem BIO 2018 in Boston as a must attend. However, I need your help to pull this off. The only question is: Will your participation be active — or passive?

  • Life, Liberty, And The Pursuit Of Healthiness
    Life, Liberty, And The Pursuit Of Healthiness

    A little over two years ago, my wife’s employer informed her that, if I was able to get health insurance through my employer, I would have to do so. We didn’t think much about the change until my wife went to pick up a prescription for me in January 2016.

  • Behind The Scenes Of Allergan’s Social Contract
    Behind The Scenes Of Allergan’s Social Contract

    The story behind Allergan’s bold decision to formalize its social contract with patients told to our Chief Editor by Brent Saunders, Allergan’s chairman, president, and CEO.

  • P3s: How To Get The Good …Without The Bad
    P3s: How To Get The Good …Without The Bad

    At this year’s BIO International Convention in San Diego (June 19 – 22), I moderated a session, Navigating A Clear Path To Public-Private Partnerships, and we talked about the good, the bad, and the ugly of P3s. After a brief introduction, the first question was posed, resulting in the following edited dialogue.

  • My Top 10 Quotes From David Hung, Axovant Sciences CEO
    My Top 10 Quotes From David Hung, Axovant Sciences CEO

    Forbes once called Merck’s Ken Frazier a “quote machine,” but I’d say David Hung is just as deserving of that moniker. I interviewed Hung, the new CEO of Axovant Sciences, at the BIO conference in June, and throughout our discussion I found myself smiling. Hung, who saw the company he founded, Medivation, be acquired by Pfizer for $14.3 billion, will be the subject of a Life Science Leader magazine exclusive feature in our October 2017 issue. During our conversation he provided a plethora of statements I found so memorable that I decided to put together a list of my top 10 favorites — listed in the order they occurred during conversation.

Rob Wright

Rob Wright



Rob Wright is the chief editor of Life Science Leader magazine. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, co-chaired, moderated, and served as a speaker at industry and academic conferences and is the past co-chair for the 2015 BIO International conference educational planning committee. Wright’s 100+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma.